Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

“…Median prior regimens, n (range) 5 (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18) .2 previous regimens, n (%) 637 (93.4)…”

“…Thus, despite being a heavily pretreated population, patients who progress following treatment in this study may be medically fit enough to tolerate additional treatments. Indeed, the pomalidomide and low-dose dexamethasone regimen has been shown to improve and prolong health-related quality of life vs high-dose dexamethasone in the MM-003 study, 16,17 which may make it possible for patients to tolerate subsequent treatments that might not otherwise have been an option.…”

A systematic review of health‐related quality of life in longitudinal studies of myeloma patients

“…These data are presented in three of the included studies. 23,39,59 After the literature search for this systematic review was completed, an additional analysis of the HRQoL data from the ASPIRE trial is published including these aspects. 60 Confidence intervals (95%) or standard deviations are reported in 15 of the 23 publications and the standard deviations ranged up to 34 on a 0-100 point scale.…”

Pomalidomide in the Management of Relapsed Multiple Myeloma

“…A subanalysis of the MM-003 trial revealed comparable efficacy and safety of Pom/Dex in patients with moderate renal insufficiency (creatinine clearance between 30 and 60 ml/mn) in comparison with those with normal renal function [42]. Similar results have been reported in a pooled analyses of three clinical trials, including MM-003, using Pom/Dex in relapsed myeloma patients [48].…”

“…With adequate thrombosis prophylaxis, the rate of DVT was low (2%). Finally, the prospective analysis of patients' quality of life (QoL) in this trial demonstrated a significant advantage for patients treated in the Pom/Dex arm (vs HDD), with no negative impact on QoL over the course of treatment [41,42]. Taken Overall, pomalidomide is well tolerated with only few patients discontinuing the drug due to treatment-related adverse event in the trials reported above [5, [29][30].…”